We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

96 hedge funds and large institutions have $757M invested in Aimmune Therapeutics in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 21

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

7% more funds holding

Funds holding: 90 → 96 (+6)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

2% less capital invested

Capital invested by funds: $771M → $757M (-$13.5M)

Holders
96
Holders Change
+6
Holders Change %
+6.67%
% of All Funds
2.39%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
13
Increased
45
Reduced
21
Closed
7
Calls
$252K
Puts
–
Net Calls
+$252K
Net Calls Change
-$51K

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$13.7M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$12.6M
3
BlackRock
BlackRock
New York
+$9M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6M
5
GPP
Great Point Partners
Connecticut
+$5.97M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$50.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.14M
3
Credit Agricole
Credit Agricole
France
-$8.99M
4
TG
TLP Group
Illinois
-$1.91M
5
AG
Artal Group
Luxembourg
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
Swiss National Bank
51
Swiss National Bank
Switzerland
$760K – – –
SO
52
STRS Ohio
Ohio
$711K +$38.2K +2,000 +6%
CS
53
Credit Suisse
Switzerland
$645K -$211K -11,051 -26%
HP
54
Hikari Power
Japan
$617K +$572K +30,000 New
ProShare Advisors
55
ProShare Advisors
Maryland
$595K +$63K +3,303 +13%
PPA
56
Parametric Portfolio Associates
Washington
$576K -$300K -15,713 -36%
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$570K +$128K +6,690 +32%
Commonwealth Equity Services
58
Commonwealth Equity Services
Massachusetts
$539K – – –
Russell Investments Group
59
Russell Investments Group
United Kingdom
$532K -$127K -6,682 -21%
State of Wisconsin Investment Board
60
State of Wisconsin Investment Board
Wisconsin
$514K +$477K +25,000 New
EVM
61
Eaton Vance Management
Massachusetts
$513K – – –
MLICM
62
Metropolitan Life Insurance Company (MetLife)
New York
$509K +$102K +5,372 +28%
RJA
63
Raymond James & Associates
Florida
$473K +$95K +4,982 +28%
Citigroup
64
Citigroup
New York
$471K +$178K +9,330 +69%
AIG
65
American International Group
New York
$449K +$108K +5,643 +35%
GCP
66
GSA Capital Partners
United Kingdom
$442K +$410K +21,500 New
Federated Hermes
67
Federated Hermes
Pennsylvania
$411K – – –
NFA
68
Nationwide Fund Advisors
Ohio
$409K -$3.78K -198 -1%
SSA
69
Schonfeld Strategic Advisors
New York
$407K +$378K +19,840 New
Citadel Advisors
70
Citadel Advisors
Florida
$360K +$334K +17,530 New
VEA
71
Virtus ETF Advisers
New York
$334K +$72.3K +3,789 +30%
DekaBank Deutsche Girozentrale
72
DekaBank Deutsche Girozentrale
Germany
$333K +$301K +15,800 New
VOYA Investment Management
73
VOYA Investment Management
Georgia
$324K +$71.7K +3,757 +31%
AQR Capital Management
74
AQR Capital Management
Connecticut
$290K +$269K +14,096 New
FSA
75
Franklin Street Advisors
North Carolina
$220K -$191K -10,000 -48%
1 2
3
4 5

AIMT Hedge Fund Activity: Q2 2017 in Review

96 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2017, worth a combined $757M — down 1.8% from $771M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AIMT positions and 7 closed out — a net gain of 6 holders — while 45 added to existing stakes and 21 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $13.7M. The largest seller was Wellington Management Group, exiting entirely with an estimated $50.3M sold.

  • 96 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2017, up from 90 in Q1 2017.
  • Funds reported $757M of Aimmune Therapeutics stock for Q2 2017, down 1.8% quarter-over-quarter.
  • 13 funds opened new Aimmune Therapeutics positions in Q2 2017 and 7 closed out, a net change of +6 holders.
  • The largest Aimmune Therapeutics buyer in Q2 2017 was Eventide Asset Management, an estimated $13.7M added.
  • The largest Aimmune Therapeutics seller in Q2 2017 was Wellington Management Group, an estimated $50.3M sold.

Based on aggregated 13F filings for Q2 2017.